زراعة النخاع العظمي

What is Haploidentical HSCT?

When a perfectly matched related or unrelated donor is not available, a half-matched family member (parent, child, sibling) can serve as donor. Post-transplant cyclophosphamide revolutionized haplo-HSCT, making outcomes comparable to matched donor transplants.

Why China?

• Global leadership: Peking University Institute of Hematology (Prof. Huang Xiaojun) developed the "Beijing Protocol" — most successful haplo platform worldwide
• Cost: $80,000-$130,000 vs. $300,000-$500,000 in the US
• No waiting for donor: Transplant scheduled as soon as medically indicated
• High volume: PUMC Hematology and Changhai perform 500+ allo-HSCTs/year each

Who is a candidate?

• Acute leukemia (AML, ALL) in remission — no matched donor
• High-risk MDS
• Severe aplastic anemia
• Lymphoma after autologous failure
• Inherited immune deficiencies, thalassemia major

Outcomes

Engraftment: 95%+. Grade III-IV acute GVHD: 10-15%. Moderate-severe chronic GVHD: 25-30%. 3-year OS for AML in CR: 60-70% (comparable to matched sibling). Relapse rate: 20-30%.